eligibility_summary
Adults (≥18) with CD19/20+ B‑cell NHL (DLBCL NOS, PMBCL, tFL, HGBL DH/TH or NOS, FL3B), R/R after ≥2 lines or post‑ASCT relapse, ≥1 measurable lesion (Lugano 2014), adequate organ/marrow. Exclude prior allo‑HSCT, ASCT <12 wks pre‑apheresis, CNS disease, stroke/seizure <6 mo, autoimmune/immunodeficiency/immunosuppressants, uncontrolled infection, active HBV/HCV, HIV/syphilis, severe organ/metabolic disease, inadequate washout, prior CAR‑T.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study: Phase 1b/2, single-arm, open-label in relapsed/refractory large B-cell lymphoma. Intervention: Prizloncabtagene autoleucel (Prizlon-cel, C-CAR039), an autologous, second-generation bispecific CAR-T cell therapy (biologic). Mechanism: Patient T cells are engineered to express a CAR that binds both CD19 and CD20 on B cells, engagement activates T-cell cytotoxicity via the CD3 zeta signaling domain, while the 4-1BB costimulatory domain enhances expansion, persistence, and durability. Administration: Single IV infusion after lymphodepletion. Targets/pathways: Malignant B cells expressing CD19 and/or CD20, T-cell activation (CD3 zeta) and 4-1BB (TNFRSF9) costimulation pathways, expected on-target B-cell aplasia. Goals: Phase 1b defines the recommended Phase 2 dose, Phase 2 evaluates efficacy.